...
首页> 外文期刊>Pharmacogenetics and genomics >Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting
【24h】

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

机译:整合药物基因组学测试在精神科门诊环境中支持治疗重度抑郁症的实用程序

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: The objective was to evaluate the potential benefit of an integrated, five-gene pharmacogenomic test and interpretive report (GeneSight) for the management of psychotropic medications used to treat major depression in an outpatient psychiatric practice. METHODS: The open-label study was divided into two groups. In the first (unguided) group (n=113), pharmacogenomic information was not shared until all participants completed the study. In the second (guided) group (n=114), the pharmacogenomic report was provided to physicians for clinical use. Three depression ratings, the 17-item Hamilton Rating Scale for Depression (HAMD-17), the Quick Inventory of Depressive Symptomatology - Clinician Rated (QIDS-C16), and the Patient Health Questionnaire (PHQ-9), were collected at baseline, and at 2, 4, and 8 weeks. RESULTS: The guided group experienced greater percent improvement in depression scores from baseline on all three depression instruments (HAMD-17, P<0.0001; QIDS-C16, P<0.0001; PHQ-9, P<0.0001) compared with the unguided group. Eight-week response rates were higher in the guided group than in the unguided group on all three measurements (HAMD-17, P=0.03; QIDS-C16, P=0.005; PHQ-9, P=0.01). Eight-week QIDS-C16 remission rates were higher in the guided group (P=0.03). Participants in the unguided group who at baseline were prescribed a medication that was most discordant with their genotype experienced the least improvement compared with other unguided participants (HAMD-17, P=0.007). Participants in the guided group and on a baseline medication most discordant with their genotype showed the greatest improvement compared with the unguided cohort participants (HAMD-17, P=0.01). CONCLUSION: These findings replicate previous studies and demonstrate significantly improved depression outcomes with use of GeneSight, an integrated, multigenetic pharmacogenomic testing platform.
机译:目的:目的是评估一种综合的五基因药物基因组学测试和解释性报告(GeneSight)对门诊精神病学治疗重大抑郁症的精神药物管理的潜在益处。方法:开放标签研究分为两组。在第一个(非指导)组(n = 113)中,直到所有参与者都完成了研究后才分享药物基因组学信息。在第二组(指导组)(n = 114)中,药物基因组学报告已提供给医生用于临床。在基线时,收集了三个抑郁评分,17个项的汉密尔顿抑郁评分量表(HAMD-17),抑郁症状快速清单-临床医师评分(QIDS-C16)和患者健康问卷(PHQ-9),在第2、4和8周。结果:与非指导组相比,在所有三种抑郁仪器(HAMD-17,P <0.0001; QIDS-C16,P <0.0001; PHQ-9,P <0.0001)上,指导组的抑郁评分均较基线水平有更大的改善。在所有三个测量中,引导组的八周响应率均高于非引导组(HAMD-17,P = 0.03; QIDS-C16,P = 0.005; PHQ-9,P = 0.01)。指导组的八周QIDS-C16缓解率更高(P = 0.03)。与其他无指导的参与者相比,接受基础治疗的非指导性参与者在基线时的处方与他们的基因型最不相符的治疗效果改善最小(HAMD-17,P = 0.007)。与未接受指导的队列参与者相比,接受指导的小组的参与者和使用与他们的基因型最不一致的基线药物的患者表现出最大的改善(HAMD-17,P = 0.01)。结论:这些发现重复了以前的研究,并证明使用集成多基因药物基因组学测试平台GeneSight可以显着改善抑郁症的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号